1.09
-0.02(-1.80%)
Currency In USD
| Previous Close | 1.11 |
| Open | 1.09 |
| Day High | 1.09 |
| Day Low | 1.08 |
| 52-Week High | 11.76 |
| 52-Week Low | 0.94 |
| Volume | 5,116 |
| Average Volume | 680,938 |
| Market Cap | 52.04M |
| PE | -0.71 |
| EPS | -1.53 |
| Moving Average 50 Days | 1.21 |
| Moving Average 200 Days | 4.71 |
| Change | -0.02 |
If you invested $1000 in Shattuck Labs, Inc. (STTK) since IPO date, it would be worth $56.33 as of December 26, 2024 at a share price of $1.09. Whereas If you bought $1000 worth of Shattuck Labs, Inc. (STTK) shares 3 years ago, it would be worth $126.6 as of December 26, 2024 at a share price of $1.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shattuck Labs Announces Participation in Upcoming December Conferences
GlobeNewswire Inc.
Nov 25, 2024 12:00 PM GMT
AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
GlobeNewswire Inc.
Oct 01, 2024 10:30 AM GMT
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azaciti